Studies find that multiple purchases by C-level executives signal strong annualized returns.
|
United Homes Group, Inc. – SYM: UHG Recent Price: $4.47
Insider Action: 4 insiders buy $4.8 mil in shares Description: United Homes Group, Inc., a homebuilding company, engages in the design, building, and sale of homes in South Carolina, North Carolina, and Georgia. It provides detached single-family houses, as well as attached single-family houses, including duplex and town houses for entry-level buyers, first time move-ups, second time move-ups, third time move-ups, and custom builds. The company was founded in 2004 and is headquartered in Chapin, South Carolina. |
enVVeno Medical Corporation – SYM: NVNO Recent Price: $3.18
Insider Action: 5 insiders buy $330K in shares Description: enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California. |
iBio, Inc. – SYM: IBIO Recent Price: $2.86
Insider Action: 7 insiders buy $654K in shares Description: iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
|
|
Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2024 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
Click here to unsubscribe |
|
|
|
